PMCB Kenneth L. Waggoner, Chief Executive Officer
Post# of 25228
Posted On: 01/23/2015 8:32:43 AM
PMCB Kenneth L. Waggoner, Chief Executive Officer of PharmaCyte Biotech, said, "This article brings together all of the promising treatments currently in development for pancreatic cancer, and we are pleased that our therapy, which is being advanced with the help of our partner Austrianova, is among them. It is noteworthy that our successful approach to treat ascites resulting from pancreatic and other solid tumors is also mentioned."
Brower's article notes that even more effort is needed to develop new pancreatic cancer treatments because by 2030, the disease, which is currently the fifth leading cause of cancer-related deaths in the U.S., could rise to number two on that list.
Brower's article notes that even more effort is needed to develop new pancreatic cancer treatments because by 2030, the disease, which is currently the fifth leading cause of cancer-related deaths in the U.S., could rise to number two on that list.
(0)
(0)
Consider all my posts my opinion and not advice to buy or sell anything. I post on stocks I own or am considering owning. Do your own DD!
